5-bromo-1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)uracil | 55612-18-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 5-bromo-1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)uracil
• 英文别名: 5-bromo-2'-fluoro-2'-deoxy-uridine；5-Brom-2'-fluor-2'-deoxyuridin；5-Bromo-2'-deoxy-2'-fluorouridine；5-bromo-1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• CAS: 55612-18-5
• 化学式: C₉H₁₀BrFN₂O₅
• 分子量: 325.091
• InChiKey: WFOXFPXBLFRFHB-UAKXSSHOSA-N

物化性质

• 密度：
  1.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 储存条件：
  2-8℃

制备方法与用途

5-溴-2′-脱氧-2′-氟尿苷（实施例1）是一种5-卤代类似物，可能成为抗病毒药物。

反应信息

• 作为反应物：
  描述：

  5-bromo-1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)uracil 在 N-氯代丁二酰亚胺 、 <82Br>NH4Br 、 溶剂黄146 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以57%的产率得到<(82)Br>-5-bromo-1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)uracil
  参考文献：
  名称：

  Synthesis and tumor uptake of 5-bromine-82- and 5-iodine-131-labeled 5-halo-1-(2-fluoro-2-deoxy-.beta.-D-ribofuranosyl)uracils

  摘要：

  A synthesis of 5-bromo- and 5-iodo-1-(2-fluoro-2-deoxy-beta-D-ribofuranosyl)uracil (3 and 4) and their 5-82Br and 5-131I analogues has been developed. The tissue distribution of the radiolabeled compounds in BDF1 mice bearing Lewis lung tumors has been investigated. After injection of the radiolabeled analogues of compounds 3 and 4 there was a rapid initial excretion of activity. Compound 3 was excreted unchanged in the urine. Residual activity in mice after 4 h showed a distribution characteristic of bromide (Br-). Compound 4 was excreted mainly as unchanged starting material with increasing amounts of iodide (I-) detected at later time periods, in addition to 5-iodouridine and unidentified metabolites at shorter time periods. Both 3 and 4 demonstrated a remarkable in vivo stability relative to related 5-substituted nucleosides that do not contain the 2'-fluoro group. The tumor uptake was minimal, with only the 5-bromo analogue demonstrating a slight elevation in tumor to blood ratios relative to other tissues. Compounds 3 and 4 were shown to compete with thymidine for the same binding site in the transport of nucleosides across the cell membrane in mouse erythrocytes. The inhibition constants (Ki) show that the compounds were weak competitors of thymidine binding to pyrimidine nucleoside transporter compared to physiological nucleosides. Other evidence indicates that compounds 3 and 4 are not substrates for mammalian kinase enzymes.

  DOI：

  10.1021/jm00126a024
• 作为产物：
  描述：

  2'-氟-2'-脱氧尿苷 在 ammonium hydroxide 、 溴 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 5-bromo-1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)uracil
  参考文献：
  名称：

  Synthesis and tumor uptake of 5-bromine-82- and 5-iodine-131-labeled 5-halo-1-(2-fluoro-2-deoxy-.beta.-D-ribofuranosyl)uracils

  摘要：

  A synthesis of 5-bromo- and 5-iodo-1-(2-fluoro-2-deoxy-beta-D-ribofuranosyl)uracil (3 and 4) and their 5-82Br and 5-131I analogues has been developed. The tissue distribution of the radiolabeled compounds in BDF1 mice bearing Lewis lung tumors has been investigated. After injection of the radiolabeled analogues of compounds 3 and 4 there was a rapid initial excretion of activity. Compound 3 was excreted unchanged in the urine. Residual activity in mice after 4 h showed a distribution characteristic of bromide (Br-). Compound 4 was excreted mainly as unchanged starting material with increasing amounts of iodide (I-) detected at later time periods, in addition to 5-iodouridine and unidentified metabolites at shorter time periods. Both 3 and 4 demonstrated a remarkable in vivo stability relative to related 5-substituted nucleosides that do not contain the 2'-fluoro group. The tumor uptake was minimal, with only the 5-bromo analogue demonstrating a slight elevation in tumor to blood ratios relative to other tissues. Compounds 3 and 4 were shown to compete with thymidine for the same binding site in the transport of nucleosides across the cell membrane in mouse erythrocytes. The inhibition constants (Ki) show that the compounds were weak competitors of thymidine binding to pyrimidine nucleoside transporter compared to physiological nucleosides. Other evidence indicates that compounds 3 and 4 are not substrates for mammalian kinase enzymes.

  DOI：

  10.1021/jm00126a024

文献信息

• Thymidine analogs for imaging
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP1916003A1

  公开（公告）日：2008-04-30

  The present invention relates to nucleoside analogues and more particularly to labelled nucleoside analogues of formula (I). It has been found new thymidine analogues can be stably labelled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and I or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.

  本发明涉及核苷类似物，更特别地涉及式(I)的标记核苷类似物。已发现新的胸苷类似物可以稳定地标记具有可检测标记基团。此外，本发明涉及制备上述化合物的方法以及利用这些化合物进行肿瘤细胞的诊断成像和/或治疗增殖性疾病。此外，本发明涉及制备和使用正电子发射化合物进行正电子发射断层扫描（PET）。还公开了一种试剂盒。
• THYMIDINE ANALOGS FOR IMAGING
  申请人：SRINIVASAN Ananth

  公开号：US20080170993A1

  公开（公告）日：2008-07-17

  The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and/or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.

  本发明涉及核苷类似物，更具体地涉及标记的核苷类似物。已发现新的胸腺嘧啶类似物可以稳定地标记为可检测的标记基团。此外，本发明还涉及制备上述化合物的方法以及利用这些化合物进行肿瘤细胞的诊断成像和/或增殖性疾病的治疗的用途。此外，本发明还涉及正电子发射剂的制备和应用于正电子发射断层扫描（PET）的用途。还公开了一种试剂盒。
• 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them
  申请人：Sloan-Kettering Institute For Cancer Research

  公开号：EP0010205A1

  公开（公告）日：1980-04-30

  1. Pyrimidine nucleosides exhibiting anti-viral and anti-tumor effects have the formula wherein A is OR', SR', NR3R4 or NHacyl wherein R' and R' are the same or different and are hydrogen, lower alkyl of 1 to 7 carbon atoms, aralkyl, or aryl; NHacyl is alkanoyl or aroyl amide; B is oxygen or sulfur; X is halogen, alkylsulfonyl or arylsulfonyl; Y is halogen, amino, monoalkyl- or monoaralkylamino, dialkylamino, aminomethyl, hydroxymethyl, lower alkyl, aryl, aralkyl, vinyl and substituted vinyl or ethynyl and substituted ethynyl; Z is methyne or nitrogen; R1 and R2 are the same or different and are hydrogen acyl or aroyl.

  1.具有抗病毒和抗肿瘤作用的嘧啶核苷的化学式为 其中 A是OR'、SR'、NR3R4或NHacyl，其中R'和R'相同或不同，并且是氢、1至7个碳原子的低级烷基、芳基或芳基； NHacyl 是烷酰基或芳基酰胺； B 是氧或硫； X 是卤素、烷基磺酰基或芳基磺酰基； Y 是卤素、氨基、单烷基或单芳基氨基、二烷基氨基、氨甲基、羟甲基、低级烷基、芳基、芳烷基、乙烯基和取代乙烯基或乙炔基和取代乙炔基； Z 是甲基或氮； R1 和 R2 相同或不同，并且是氢酰基或芳基。
• MERCER, JOHN R.;XU, LI-HUA;KNAUS, EDWARD E.;WIEBE, LEONARD I., J. MED. CHEM., 32,(1989) N, C. 1289-1294
  作者：MERCER, JOHN R.、XU, LI-HUA、KNAUS, EDWARD E.、WIEBE, LEONARD I.

  DOI：——

  日期：——
• SYNTHESIS OF 2'-DEOXY-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU)
  申请人：University of Southern California

  公开号：EP2603516A2

  公开（公告）日：2013-06-19